Thyas has raised JPY 200 million in Series A1 financing on September 06, with participation from Kyoto University Innovation Capital Co., Ltd., and SMBC Venture Capital Co., Ltd.

The funds will be used for accelerating the research and development including establishment of cell production methods and preparation of preclinical studies of iPS cell-derived T cell therapy for the treatment of solid cancers.